A COMPARATIVE STUDY ON COMMERCIAL BARBALOIN AND ISOLATED BARBALOIN FROM ALOE VERA FOR IN VIVO ANTI-DIABETIC AND ANTI-CANCER ACTIVITY

IVY GHOSH; HIMANGSHU SEKHAR MAJI; ARIJIT MONDAL; DIBYA DAS; DEBDIP MANDAL

doi:10.22159/ajpcr.2025v18i9.55995

Authors

IVY GHOSH Department of Pharmaceutical Technology, JIS University, Kolkata, West Bengal, India.
HIMANGSHU SEKHAR MAJI Department of Pharmaceutical Technology, JIS University, Kolkata, West Bengal, India.
ARIJIT MONDAL Department of Pharmaceutical Technology, M. R. College of Pharmaceutical Sciences and Research, Bira, West Bengal, India.
DIBYA DAS Department of Pharmaceutical Technology, JIS University, Kolkata, West Bengal, India.
DEBDIP MANDAL Department of Pharmaceutical Technology, M. R. College of Pharmaceutical Sciences and Research, Bira, West Bengal, India.

DOI:

https://doi.org/10.22159/ajpcr.2025v18i9.55995

Keywords:

Ehrlich ascites carcinoma, Hyperglycemia, Cancer, Traditional medicine

Abstract

Objectives: The fundamental objective of this research is to provide a thorough assessment of the anti-diabetic and anti-cancer properties of both commercial and isolated barbaloin obtained from Aloe vera. The study examines the usefulness of barbaloin, a significant secondary metabolite, in alleviating difficulties related to diabetes and cancer, in light of the growing worldwide interest in plant-based, non-toxic treatments.

Methods: The structure elucidation of the isolated molecule was performed using Fourier transform infrared, high-resolution mass spectrometry, and NMR. The experimental strategy incorporates in vivo experiments using streptozotocin-induced diabetic rats and Ehrlich ascites carcinoma (EAC) tumor models. Diabetic rats received varying dosages of isolated and commercial barbaloin, in conjunction with the common anti-diabetic medication glyburide, to evaluate their effects on blood glucose levels, serum biomarkers, and lipid profiles over 28-day duration.

Results: The findings indicated substantial decreases in blood glucose, serum enzymes, and lipid levels in the barbaloin-treated groups relative to untreated diabetic controls, indicating strong anti-hyperglycemic efficacy. Biochemical tests indicated enhancements in liver function indicators and oxidative stress parameters, corroborating the therapeutic efficacy of barbaloin in mitigating diabetes consequences. Simultaneous anti-cancer studies included the injection of EAC cells into rats, followed by treatment with different dosages of A. vera extract and barbaloin. The results indicated a significant reduction in tumor burden and improved survival rates, suggesting that barbaloin has substantial cytotoxic properties against cancer cells. The standard barbaloin reduced tumor volume by 85.4% and viable tumor cell count by 92.3%, isolated barbaloin reduced these parameters by 72.1% and 82.6%, respectively.

Conclusion: The research emphasizes the prospective therapeutic potential of barbaloin in the management of diabetes and cancer, indicating its viability as a safe, plant-based alternative or complement to traditional therapies.

Downloads

Download data is not yet available.

References

1. Zeng L, Ding H, Hu X, Zhang G, Gong D. Galangin inhibits α-glucosidase activity and formation of non-enzymatic glycation products. Food Chem. 2019 Jan 15;271:70-9. doi: 10.1016/j. foodchem.2018.07.148, PMID 30236734

2. Joglekar MM, Bavkar LN, Sistla S, Arvindekar AU. Effective inhibition of protein glycation by combinatorial usage of limonene and aminoguanidine through differential and synergistic mechanisms. Int J Biol Macromol. 2017 Jun 1;99:563-9. doi: 10.1016/j. ijbiomac.2017.02.104, PMID 28274869

3. Kellow NJ, Coughlan MT. Effect of diet-derived advanced glycation end products on inflammation. Nutr Rev. 2015 Nov 1;73(11):737-59. doi: 10.1093/nutrit/nuv030, PMID 26377870

4. Muñiz A, Garcia E, Gonzalez D, Zuñiga L. Antioxidant activity and in vitro antiglycation of the fruit of Spondias purpurea. Evid Based Complement Alternat Med. 2018;2018(1):5613704. doi: 10.1155/2018/5613704, PMID 30228828

5. Khalifah RG, Baynes JW, Hudson BG. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun. 1999 Apr 13;257(2):251-8. doi: 10.1006/bbrc.1999.0371, PMID 10198198

6. Ochwang’i DO, Kimwele CN, Oduma JA, Gathumbi PK, Mbaria JM, Kiama SG. Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. J Ethnopharmacol. 2014 Feb 12;151(3):1040- 55. doi: 10.1016/j.jep.2013.11.051, PMID 24362078

7. Evans HS, Møller H, Robinson D, Lewis CM, Bell CM, Hodgson SV. The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut. 2002 May 1;50(5):647-52. doi: 10.1136/gut.50.5.647, PMID 11950810

8. Greenwell M, Rahman PK. Medicinal plants: Their use in anticancer treatment. Int J Pharm Sci Res. 2015 Oct 1;6(10):4103-12. doi: 10.13040/IJPSR.0975-8232.6(10).4103-12, PMID 26594645

9. Cragg GM, Newman DJ. Medicinals for the millennia: The historical record. Ann N Y Acad Sci. 2001 Dec;953(1):3-25. doi: 10.1111/j.1749- 6632.2001.tb11356.x, PMID 11795420

10. Zhang L, Tu ZC, Xie X, Lu Y, Wang ZX, Wang H, et al. Antihyperglycemic, antioxidant activities of two Acer palmatum cultivars, and identification of phenolics profile by UPLC-QTOF-MS/ MS: New natural sources of functional constituents. Ind Crops Prod. 2016 Oct 30;89:522-32. doi: 10.1016/j.indcrop.2016.06.005

11. Langmead L, Makins RJ, Rampton DS. Anti‐inflammatory effects of Aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004 Mar;19(5):521-7. doi: 10.1111/j.1365-2036.2004.01874.x, PMID 14987320

12. Benzidia B, Barbouchi M, Hammouch H, Belahbib N, Zouarhi M, Erramli H, et al. Chemical composition and antioxidant activity of tannins extract from green rind of Aloe vera (L.) Burm. F. J King Saud Univ Sci. 2019 Oct 1;31(4):1175-81. doi: 10.1016/j.jksus.2018.05.022

13. Maan AA, Nazir A, Khan MK, Ahmad T, Zia R, Murid M, et al. The therapeutic properties and applications of Aloe vera: A review. J Herb Med. 2018 Jun 1;12:1-10. doi: 10.1016/j.hermed.2018.01.002

14. Gutterman Y, Chauser-Volfson E. The distribution of the phenolic metabolites barbaloin, aloeresin and aloenin as a peripheral defense strategy in the succulent leaf parts of Aloe arborescens. Biochem Syst

Ecol. 2000 Nov 1;28(9):825-38. doi: 10.1016/S0305-1978(99)00129-5, PMID 10913844

15. Chang XL, Wang C, Feng Y, Liu Z. Effects of heat treatments on the stabilities of polysaccharides substances and barbaloin in gel juice from Aloe vera Miller. J Food Eng. 2006 Jul 1;75(2):245-51. doi: 10.1016/j. jfoodeng.2005.04.026

16. Ghosh I, Banerjee S, Dutta S, Maji HS, Mondal A. Exploring the anti-diabetic potential of Aloe vera: Isolation and characterization of bioactive compounds. Nat Prod Res. 2025 Jan 11:1-7. doi: 10.1080/14786419.2025.2451775

17. Eleazu CO, Eleazu KC, Chukwuma S, Essien UN. Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J Diabetes Metab Disord. 2013 Dec;12(1):60. doi: 10.1186/2251-6581- 12-60, PMID 24364898

18. Racine KC, Iglesias-Carres L, Herring JA, Wieland KL, Ellsworth PN, Tessem JS, et al. The high-fat diet and low-dose streptozotocin type-2 diabetes model induces hyperinsulinemia and insulin resistance in male but not female C57BL/6J mice. Nutr Res. 2024 Nov 1;131:135-46. doi: 10.1016/j.nutres.2024.09.008, PMID 39389000

19. Skovsø S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig. 2014 Jul;5(4):349-58. doi: 10.1111/ jdi.12235, PMID 25411593

20. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010 Aug 16;6(16):1794-805. doi: 10.1002/smll.201000538, PMID 20623530

21. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, et al. A rat model of bone cancer pain. Pain. 2002 Mar 1;96(1-2):129-40. doi: 10.1016/S0304-3959(01)00437-7, PMID 11932069

22. Misawa E, Tanaka M, Nomaguchi K, Nabeshima K, Yamada M, Toida T, et al. Oral ingestion of Aloe vera phytosterols alters hepatic gene expression profiles and ameliorates obesity-associated metabolic disorders in Zucker diabetic fatty rats. J Agric Food Chem. 2012;60(11):2799-806. doi: 10.1021/jf204465j, PMID 22352711

23. Shin E, Shin S, Kong H, Lee S, Do SG, Jo TH, et al. Dietary aloe reduces adipogenesis via the activation of AMPK and suppresses obesity-related inflammation in obese mice. Immune Netw. 2011; 11(2):107-13. doi: 10.4110/in.2011.11.2.107, PMID 21637388.

24. Reveny J, Nugraha SE, Kamilia A, Nuratika. Formulation of anti-diabetic ulcer gel enriched with Aloe vera extract and fish collagen: An in vivo study. Int J Appl Pharm. 2025 Apr;17(4):435-43. doi: 10.22159/ ijap.2025v17i4.51149

25. Dimple KA, Kumar VI, Tomer VI. Traditional medicinal systems for treatment of diabetes mellitus: A review. Int J Pharm Pharm Sci. 2018 Apr; 14;10(5):7-17. doi: 10.22159/ijpps.2018v10i5.25374